Veterinary medicines
Effective and safe veterinary medicines – healthy animals
New antibiotics or medicines against fleas: We authorise veterinary medicinal products for food-producing and companion animals at national and European level. The authorisation procedure comprises assessment of efficacy, safety, quality and environmental safety to ensure the effective and safe use of VMPs. Our goal is to safeguard animal health for the benefit of humans, animals and the environment.
Get in touch! Report adverse events to the BVL
The English website on Veterinary medicines is under construction. Please refer to the German website in case desired information cannot be found here.
Many topics, one goal
Tasks in the field of veterinary medicinal products
The crisis management for veterinary medicinal products acts as an interface between European partner authorities as well as national and international stakeholders.
For users of veterinary medicinal products
In this section, animal owners will find information and advice on the use of veterinary medicinal products.
For veterinarians
In this section, veterinarians will find up-to-date information on the authorisation and marketability of veterinary medicinal products, publications, explanations and commentaries on various topics relating to animal welfare and animal health.
For applicants and companies
In this section, pharmaceutical companies and other applicants will find helpful information and forms for application procedures as well as answers to frequently asked questions.
The European Regulation on Veterinary Medicinal Products
In this section, we would like to inform you about the background as well as current developments regarding Regulation (EU) 2019/6 on veterinary medicinal products.
BVL Announcements
Find here BVL announcements on veterinary medicinal products and related topics.
FAQ Veterinary Medicines
Direct access
Frequently searched
Adverse events related to the use of veterinary medicinal products
Adverse events following the use of veterinary medicinal products should be reported to the BVL, even if a connection with the use of one or more products is only suspected.